Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2582219 | 0.83 | MEN1 (0.52) | SMN1; SMN2MEN1KMT2AKDM4EMAPT | |
| SCHEMBL12724449 | 0.83 | MEN1 (0.53) | SMN1; SMN2MEN1KMT2AKDM4EMAPT | |
| SCHEMBL17875392 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2MEN1KMT2AKDM4EMAPT | |
| SCHEMBL2200522 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2AKDM4EMAPT | |
| SCHEMBL2800809 | 0.76 | SMN1; SMN2 (0.43) | SMN1; SMN2MEN1KMT2AKDM4EMAPT | |
| SCHEMBL2729599 | 0.76 | SMN1; SMN2 (0.43) | SMN1; SMN2MEN1KMT2AKDM4EMAPT | |
| SCHEMBL3871150 | 0.76 | SMN1; SMN2 (0.43) | SMN1; SMN2MEN1KMT2AKDM4EMAPT | |
| SCHEMBL29380196 | 0.76 | SMN1; SMN2 (0.43) | SMN1; SMN2MEN1KMT2AKDM4EMAPT | |
| SCHEMBL8994564 | 0.75 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1GLAPOLBGAA | |
| SCHEMBL29882203 | 0.75 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1GLAPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106589364-A | Polyaniline nano fiber and preparation method thereof | 中国电子科技集团公司第二十六研究所 | 2017-04-26 | — | — | CN | claimed |
| US-20080275057-A1 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2008-11-06 | — | — | US | claimed |
| EP-3567035-A1 | N-SUBSTITUTED 2,5-DIOXO-AZOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Canbas Co. Ltd. (JP) | 2019-11-13 | — | — | EP | disclosed |
| CN-106589364-A | Polyaniline nano fiber and preparation method thereof | 中国电子科技集团公司第二十六研究所 | 2017-04-26 | — | — | CN | disclosed |
| CN-106589364-A | Polyaniline nano fiber and preparation method thereof | 中国电子科技集团公司第二十六研究所 | 2017-04-26 | — | — | CN | disclosed |
| EP-3088397-A1 | COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER | Canbas Co. Ltd. (JP) | 2016-11-02 | — | — | EP | disclosed |
| EP-2716351-B1 | GAS SEPARATION MEMBRANE | CENTRAL GLASS CO LTD (JP) | 2016-06-29 | — | — | EP | disclosed |
| CN-102320998-B | Phthalic diamide compounds containing 2'-hydroxy hexafluoro isopropyl group and application thereof | UNIV EAST CHINA SCIENCE & TECH | 2014-08-20 | — | — | CN | disclosed |
| EP-2748280-A1 | PHOTOREACTIVE COMPOUNDS | Rolic AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013026691-A1 | PHOTOREACTIVE COMPOUNDS | ROLIC AG (CH) | 2013-02-28 | — | — | WO | disclosed |
| WO-2010063802-A1 | 3, 4-DI-SUBSTITUTED CYCLOBUTENE- 1, 2 -DIONES AS CXCR2 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| EP-1531824-A2 | CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND USE THEREOF FOR TREATMENT OF SKIN DISORDERS | Wyeth (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050101568-A1 | Methods and compositions for selectin inhibition | WYETH (US) | 2005-05-12 | — | — | US | disclosed |
| CN-1608069-A | Fused heterocyclic succinimide compounds and analogs thereof that modulate nuclear hormone receptor function | BRISTOL MYERS SQUIBB CO (US) | 2005-04-20 | — | — | CN | disclosed |
| CN-1589271-A | Fused heterocyclic succinimide compounds and analogs thereof as modulators of nuclear hormone receptor function | BRISTOL MYERS SQUIBB CO (US) | 2005-03-02 | — | — | CN | disclosed |
| EP-1467721-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | Amgen Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | WYETH | 2004-01-22 | — | — | US | disclosed |
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH | 2004-01-08 | — | — | US | disclosed |
| WO-2004000230-A2 | CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND USE THEREOF FOR TREATMENT OF SKIN DISORDERS | WYETH (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101568-A1 | Methods and compositions for selectin inhibition | SELP, SELE, SELL | SMN1; SMN2 2880/4885MEN1 4598/4885KMT2A 4568/4885 |
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | ESRRA, GNRHR, ESRRG | SMN1; SMN2 4163/4885MEN1 402/4885KMT2A 1777/4885 |
| US-20080275057-A1 | Compounds with anti-cancer activity | CDKN1A, CDC25C, DDB1 | SMN1; SMN2 4405/4885MEN1 1177/4885KMT2A 432/4885 |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | NR5A1, MC1R, CYP17A1 | SMN1; SMN2 4857/4885MEN1 3679/4885KMT2A 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.